Articles



🕻 🖲 Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis



Lancet Diabetes Endocrinol

https://doi.org/10.1016/ \$2213-8587(24)00040-8

See Comment page 286

*Collaborators are listed at the

CTT Secretariat, Clinical Trial Service Unit and Epidemiological

Department of Population

Health, Oxford OX3 7LF, UK ctt@ndph.ox.ac.uk

2024; 12: 306-19 Published Online

March 27, 2024

end of the Article

Correspondence to:

Studies Unit, Nuffield

Cholesterol Treatment Trialists' (CTT) Collaboration*

Summary

Background Previous meta-analyses of summary data from randomised controlled trials have shown that statin therapy increases the risk of diabetes, but less is known about the size or timing of this effect, or who is at greatest risk. We aimed to address these gaps in knowledge through analysis of individual participant data from large, long-term, randomised, double-blind trials of statin therapy.

Methods We conducted a meta-analysis of individual participant data from randomised controlled trials of statin therapy that participated in the CTT Collaboration. All double-blind randomised controlled trials of statin therapy of at least 2 years' scheduled duration and with at least 1000 participants were eligible for inclusion in this meta-analysis. All recorded diabetes-related adverse events, treatments, and measures of glycaemia were sought from eligible trials. Meta-analyses assessed the effects of allocation to statin therapy on new-onset diabetes (defined by diabetes-related adverse events, use of new glucose-lowering medications, glucose concentrations, or HbA_{ic} values) and on worsening glycaemia in people with diabetes (defined by complications of glucose control, increased use of glucose-lowering medication, or HbA_{1c} increase of $\ge 0.5\%$). Standard inverse-variance-weighted meta-analyses of the effects on these outcomes were conducted according to a prespecified protocol.

Findings Of the trials participating in the CTT Collaboration, 19 trials compared statin versus placebo (123 940 participants, 25701 [21%] with diabetes; median follow-up of 4.3 years), and four trials compared more versus less intensive statin therapy (30724 participants, 5340 [17%] with diabetes, median follow-up of 4.9 years). Compared with placebo, allocation to low-intensity or moderate-intensity statin therapy resulted in a 10% proportional increase in new-onset diabetes (2420 of 39179 participants assigned to receive a statin [1.3% per year] vs 2214 of 39266 participants assigned to receive placebo [1.2% per year]; rate ratio [RR] 1.10, 95% CI 1.04-1.16), and allocation to high-intensity statin therapy resulted in a 36% proportional increase (1221 of 9935 participants assigned to receive a statin [4.8% per year] vs 905 of 9859 participants assigned to receive placebo [3.5% per year]; 1.36, 1.25–1.48). For each trial, the rate of newonset diabetes among participants allocated to receive placebo depended mostly on the proportion of participants who had at least one follow-up HbA_{tc} measurement; this proportion was much higher in the high-intensity than the lowintensity or moderate-intensity trials. Consequently, the main determinant of the magnitude of the absolute excesses in the two types of trial was the extent of HbA₁, measurement rather than the proportional increase in risk associated with statin therapy. In participants without baseline diabetes, mean glucose increased by 0.04 mmol/L with both lowintensity or moderate-intensity (95% CI 0.03-0.05) and high-intensity statins (0.02-0.06), and mean HbA_{ic} increased by 0.06% (0.00-0.12) with low-intensity or moderate-intensity statins and 0.08% (0.07-0.09) with high-intensity statins. Among those with a baseline measure of glycaemia, approximately 62% of new-onset diabetes cases were among participants who were already in the top quarter of the baseline distribution. The relative effects of statin therapy on new-onset diabetes were similar among different types of participants and over time. Among participants with baseline diabetes, the RRs for worsening glycaemia were 1.10 (1.06-1.14) for low-intensity or moderate-intensity statin therapy and 1.24 (1.06–1.44) for high-intensity statin therapy compared with placebo.

Interpretation Statins cause a moderate dose-dependent increase in new diagnoses of diabetes that is consistent with a small upwards shift in glycaemia, with the majority of new diagnoses of diabetes occurring in people with baseline glycaemic markers that are close to the diagnostic threshold for diabetes. Importantly, however, any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia (or, indeed, from any other mechanism) are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials. These findings should further inform clinical guidelines regarding clinical management of people taking statin therapy.

Funding British Heart Foundation, UK Medical Research Council, and Australian National Health and Medical **Research Council.**

Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Research in context

Evidence before this study

We searched Medline and the Cochrane Central Register of Controlled Trials for randomised trials and meta-analyses published between Jan 1, 1990, and April 1, 2022, that specifically assessed the effects of statin regimens on new-onset diabetes and worsening glycaemia. For example, to identify meta-analyses in Medline, we used the BMJ systematic review search strategy in combination with ("statin.mp." or "exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/") and ("exp Diabetes Mellitus, Type 1/" or "diabet*.mp" or "exp Diabetes Mellitus/"). Meta-analyses published up until April, 2022, have used summary data from randomised controlled trials to assess the effects of statin therapy on new-onset diabetes. These analyses suggested that statin therapy increases the likelihood of new-onset diabetes being diagnosed, with more intensive statin therapy leading to larger increases. However, they had insufficient detail to investigate these findings in depth, including which individuals were at particular risk, when the effect emerged and its persistence, the effects of different statin regimens, and the effects on glycaemic control in individuals with diabetes.

Added value of this study

Obtaining individual participant data on all recorded diabetes-related adverse events and treatments, along with serial glycaemia measures, from large, long-term, blinded, randomised controlled trials has allowed the effect of statin therapy on the development of new-onset diabetes and worsening glycaemia to be assessed more comprehensively than has previously been possible with summary level data. Low-intensity or moderate-intensity regimens resulted in a 10% relative increase in new-onset diabetes compared with placebo, and high-intensity statin regimens resulted in a 36% relative increase. These increases persisted when biochemically determined diagnoses of diabetes were excluded. The rate ratios were consistent with a small increase in glycaemia due to statin therapy. These effects were widely generalisable to the different types of participants studied and persisted while treatment continued. The absolute excesses for new-onset diabetes were highest among those individuals in whom measures of glycaemia were already close to the diagnostic threshold for diabetes. Within each trial, the main determinant of the magnitude of the absolute excess was the proportion of trial participants having at least one follow-up HbA_{1c} measurement rather than the proportional increase in risk associated with statin therapy. Any theoretical adverse effects of statins on cardiovascular risk that might arise from these small increases in glycaemia (or, indeed, from any other mechanism) are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials. Our analyses strongly suggest that the absolute benefits of statin therapy greatly outweigh any excess risks of diabetes associated with the small increase in glycaemia they induce.

Implications of all the available evidence

Statin therapy produces a small increase in glycaemia, which translates into a moderate increase in the rate at which individuals are diagnosed with new-onset diabetes (or worsening glycaemic control among those with diabetes). The mean changes in glycaemia are small, and the evidence of the beneficial effects on major vascular events provides reassurance about the net benefits of using statin therapy in individuals who are at increased risk of developing diabetes or have already developed it.

Introduction

Atherosclerotic cardiovascular disease is a leading cause of death worldwide, and LDL cholesterol is a major causal risk factor.¹ Diabetes substantially increases the risk of atherosclerotic cardiovascular disease.² Randomised controlled trials have shown that prolonged reduction of LDL cholesterol concentrations with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A) reductase inhibitor (ie, a statin) reduces the incidence of myocardial infarction and ischaemic stroke by about a quarter for every 1 mmol/L reduction in LDL cholesterol,³ with consistent effects in individuals with and without diabetes.⁴

Statins have few confirmed adverse effects,⁵ but metaanalyses of summary data in published reports from large randomised controlled trials of statin therapy indicated that standard statin regimens increased the risk of newonset diabetes by about 10% compared with placebo or usual care⁶ and that more intensive statin regimens produced a further 10% relative increase in risk.⁷ However, due to the limited information available for these metaanalyses of summary data, assessment of the effects of statin therapy on the risk of developing new diabetes is incomplete. In particular, little is known about which types of people are at particularly high risk of developing diabetes due to a statin, the timing of any excess risk after commencing therapy, or the effects of statin therapy on glycaemic control in people with known diabetes.

To provide insights into these and related questions, we sought individual participant data on all recorded diabetes-related adverse events, treatments for diabetes, and measures of glycaemia recorded within the large, long-term, double-blind, randomised controlled trials of statin therapy that participate in the Cholesterol Treatment Trialists' (CTT) Collaboration.

Methods

Search strategy and selection criteria

Methods were described prospectively in the published CTT Collaboration protocol.⁸ Briefly, we conducted a meta-analysis of individual participant data from randomised controlled trials of statin therapy participating in the CTT Collaboration. Double-blind, randomised

controlled trials of statin therapy were eligible for inclusion if there were no protocol-mandated differences between treatment groups other than those created by allocation to receive statin versus placebo or allocation to receive more intensive statin therapy versus less intensive statin therapy; they involved at least 1000 participants; and there was a mean scheduled follow-up of at least 2 years. We requested individual participant data related to all adverse events recorded during the scheduled period of treatment and follow-up. These data included the timing of such events, use of other medications (including glucose-lowering medications), physical measurements, any comorbidities, and laboratory results (including glucose and HbA_{1c} values; appendix p 2).

See Online for appendix

For more on the Medical Dictionary for Regulatory Activities see https://www.meddra.org **Data analysis** We converted data into a common domain-based format on the basis of the Clinical Data Interchange Standards Consortium Study Data Tabulation Model ^{9,10} and all

on the basis of the Clinical Data Interchange Standards Consortium Study Data Tabulation Model, 9.10 and all adverse event terms were mapped to the Medical Dictionary for Regulatory Activities, version 20.0 (appendix pp 3-6).¹⁰ Diabetes-related adverse events were diabetes diagnosis, diabetes-specific complications related to ketosis and glucose control, and any other diabetes-specific complications (appendix pp 3-6). Glucose-lowering drugs were identified by use of a drug dictionary based on Martindale (appendix p 7).11 Glucose concentrations were categorised according to fasting status and assumed to be non-fasting when fasting status was unknown. HbA_{ic} values were recorded as percentages rather than mmol/mol because most of the trials were conducted before the introduction of the International Federation of Clinical Chemistry and Laboratory Medicine standard units for HbA₁₀.¹²

Baseline diabetes was defined as a recorded history of diabetes, adverse event of diabetes (appendix pp 3-6) on or before the date of participant assignment to a treatment group, use of glucose-lowering medication (appendix p 7), fasting plasma glucose concentration of 7.0 mmol/L or higher or random plasma glucose of 11.1 mmol/L or higher, or HbA_{1c} value of 6.5% or higher. For participants without baseline diabetes, the outcome of new-onset diabetes was defined as the first record after participant assignment to a treatment group of an adverse event of diabetes, use of glucoselowering medication, at least two measurements (not necessarily consecutive) of fasting plasma glucose concentration 7.0 mmol/L or higher or random plasma glucose concentration of 11.1 mmol/L or higher, or at least one HbA_{1c} value of 6.5% or higher (based on widely used biochemical thresholds).^{13,14} For participants with baseline diabetes, the outcome of worsening glycaemia was defined as a recording after participant assignment to a treatment group of an adverse event relating to ketosis or complications of glucose control, an HbA_{1c} increase (from baseline) of 0.5% or higher, or escalation of glucose-lowering medication (ie, starting

such medication for participants not on medication at baseline, starting insulin for those not on insulin therapy at baseline, or an increase in the number of non-insulin glucose-lowering medications, with or without insulin). Variables for which data were extracted were specified previously.⁸

We calculated the log-rank observed-minus-expected statistic (o-e) and its variance (v) for the first occurrence of each outcome among participants assigned to a treatment group in each trial.¹⁵ The inverse-varianceweighted average of log of the rate ratio (log RR) across all trials was then calculated as S/V (with variance 1/V, and hence with 95% CI of S/V $\pm 1.96/\sqrt{V}$), where S is the sum of (o-e) over all trials and V is the sum of v over all trials. This approach gives nearly identical estimates to the hazard ratio from a trial-stratified Cox regression model. Prespecified subgroup analyses included analyses according to particular baseline participant characteristics, by year of treatment, and for different statin regimens or intensities. Standard χ^2 tests for heterogeneity (or trend) in the log RR were conducted to assess whether the effect in any given subgroup differed materially from the overall effect seen in all participants.¹⁵ Exploratory analyses examined the effects of weighting each trial by the trial-specific absolute LDL cholesterol concentration difference at 1 year (as previously described).3 Overall RRs are reported with 95% CIs, but all other RRs (eg, in subgroup analyses) are reported with 99% CIs to provide some allowance for multiple comparisons. The effects of allocation to statin therapy on mean glucose concentrations and HbA_{tc} values after assignment to a treatment group were calculated using inverse-variance-weighted metaanalyses.

In addition to the prespecified subgroup analyses, additional post-hoc analyses were done to further explore variation according to baseline levels of glycaemia by dividing participants into quartiles defined hierarchically on the basis of HbA_{ic} , fasting glucose concentration (if HbA_{ic} value was not available), or random glucose concentration (if neither HbA_{ic} value or fasting glucose concentration were available). A further post-hoc analysis explored the effect of statin therapy on mean difference in weight subdivided by statin intensity and presence of baseline diabetes.

Results are reported separately for low-intensity or moderate-intensity and high-intensity statin regimens (according to the American Heart Association– American College of Cardiology guideline definition;¹⁶ appendix p 8). Only two trials^{17,18} allowed for direct assessments of high-intensity statin versus placebo, but indirect assessments of the effects of high-intensity statin therapy were calculated as described previously.¹⁹

To estimate the average absolute effect of statin therapy on the underlying rate of particular outcomes, we applied the RR (or its lower and upper 95% CIs) to the absolute rate in the appropriate comparator group. We used the summary RRs for all statin regimens in 16 trials^{*U*,18,20-33} of statin versus placebo to estimate the absolute excess annual rate of new-onset diabetes according to quartiles of baseline glycaemia and a risk score of new-onset diabetes, developed using a Poisson regression model (with the logarithm of follow-up time set as an offset variable) that incorporated univariate predictors of new-onset diabetes (namely baseline age, sex, BMI, triglycerides, estimated glomerular filtration rate [eGFR], HDL cholesterol concentration, and glycaemia; appendix p 28).

All analyses were based on the intention-to-treat principle. Analyses were done using SAS (version 9.4) and R (version 4.1.3). In all trials, participants gave informed consent. Ethics approval for this meta-analysis was subsequently granted by the UK National Health Service Health Research Authority (21/SC/0071).

Role of the funding source

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

Of the trials in the CTT Collaboration, individual participant data were available from 19 eligible doubleblind trials^{17,18,20-36} of any statin regimen versus placebo (123940 participants; median follow-up of 4.3 years), of which 16 trials^{17,18,20-33} (117437 participants) included participants with and without a history of diabetes, and three trials³⁴⁻³⁶ (6503 participants) recruited only participants with a history of diabetes (table). One trial²⁰ (6605 participants) compared a low-intensity statin regimen with placebo, 16 trials²¹⁻³⁶ (95890 participants) compared a moderate-intensity statin with placebo, and two trials^{17,18} (21445 participants) compared a highintensity statin regimen with placebo. Among all 19 trials, 22 925 (18%) of 123 940 participants had a known history of diabetes at randomisation, and an additional 2776 (2%) participants met our definition of baseline diabetes (appendix p 9).

Individual participant data were also available from four double-blind trials³⁷⁻⁴⁰ of more versus less intensive statin regimens (30724 participants; median follow-up of 4·9 years; table). In these four trials, two trials^{39,40} (14163 participants; median follow-up of 4·1 years) compared high-intensity versus moderate-intensity statin regimens, and two trials^{37,38} (16561 participants; median follow-up of 5·6 years) compared two moderate-intensity statin regimens. Among all four trials of more versus less intensive statin, 4589 (15%) of 30724 participants had a known history of diabetes at baseline, and an additional 751 (2%) met our definition of baseline diabetes (appendix p 9).

In the 14 trials²⁰⁻³³ of low-intensity or moderate-intensity statin versus placebo that included participants without diabetes at baseline, allocation to statin therapy resulted in a 10% relative increase in new-onset diabetes

www.thelancet.com/diabetes-endocrinology Vol 12 May 2024

(2420 of 39179 participants assigned to statin therapy [1.3% per year] vs 2214 of 39266 participants assigned to placebo [1.2% per year]; RR 1.10, 95% CI 1.04–1.16), which corresponded to a mean absolute excess of 0.12% (95% CI 0.04–0.20) during each year of treatment (figure 1). The RRs were similar irrespective of the mode of diagnosis (figure 1; appendix pp 12–15).

The placebo event rate for new-onset diabetes was substantially higher in the two trials of high-intensity statin (905 of 9859 participants assigned to placebo [3.5% per year]) than in the 14 trials of low-intensity or moderate-intensity statins (1.2% per year), and this difference was driven by biochemical diagnosis of diabetes (788 of 9859 participants assigned to placebo [3.0% per year] for high-intensity statins vs 1369 of 39266 participants assigned to placebo [0.8% per year] for low-intensity or moderate-intensity statins; figure 1). Notably, in the high-intensity statin trials, HbA_{1c} was measured at least once after assignment to a treatment group in 14345 (72%) of 19794 participants without diabetes at baseline (all of which were in the JUPITER trial¹⁷) and glucose concentration was measured at least twice after assignment to a treatment group in 9785 (49%) of 19794 participants without diabetes at baseline, making a biochemical diagnosis possible. By comparison, HbA_{1c} values after assignment to a treatment group were available for just 2434 (3%) of 78445 participants and glucose concentrations after assignment to a treatment group were available for 29008 (37%) of 78445 participants in the low-intensity or moderate-intensity trials. In the two trials17,18 of highintensity statin versus placebo that included participants without baseline diabetes, allocation to statin therapy resulted in a 36% relative increase in new-onset diabetes (1221 of 9935 participants assigned to statin therapy [4.8% per year] vs 905 of 9859 participants assigned to placebo [3.5% per year]; RR 1.36, 95% CI 1.25-1.48; figure 1), representing an absolute annual excess of 1.27% (95% CI 0.88–1.69). Although the absolute excess risk of new-onset diabetes varied depending on the method of diagnosis, the RRs were broadly similar (appendix p 16).

Further information on the risks of new-onset diabetes for statin regimens of differing intensity was available from four trials of more versus less intensive statin therapy.^{37–40} Compared with less intensive statin therapy, more intensive statin therapy resulted in a 10% proportional increase in new-onset diabetes (RR 1·10, 95% CI 1·02–1·18), corresponding to an absolute annual excess of 0·22% (95% CI 0·05–0·41; appendix pp 17–18). The RR for high-intensity statin derived indirectly by combining selected trials of more versus less intensive statin and lowintensity or moderate-intensity statin versus placebo was 1·27 (95% CI 1·11–1·44; data not shown), which was similar to the estimate obtained in the direct comparison of high-intensity statin versus placebo (1·36, 1·25–1·48; figure 1).

	Year of publication of primary results	Number of participants	Treatment comparison	Median follow up, years	Mean LDL cholesterol concen- tration, mmol/L (SD)	Mean age, years (SD)	Mean BMI, kg/m² (SD)	Mean estimated GFR, mL/min per 1.73 m ² (SD)	Women, n (%)	White participants, n (%)	Participants with a history of vascular disease, n (%)	Participants with diabetes at baseline, n (%)*
Statin vs placebo (19 trials)	:	123 940	:	4·3	3.5 (0.7)	63 (8)	27.2 (4.1)	69·5 (15·0)	34533 (28%)	60152 (81%)†	59 610 (48%)	25701 (21%)
Low-intensity statin (one trial)	:	6605	:	5.0	3.9 (0.4)	58 (7)	26-9 (3-1)	65.4 (11.6)	997 (15%)	5860 (89%)	0	232 (4%)
AFCAPS/ TexCAPS ²⁰	1998	6605	Lovastatin 20-40 mg/day vs placebo	5.0	3.9 (0.4)	58 (7)	26-9 (3-1)	65.4 (11.6)	997 (15%)	5860 (89%)	0	232 (4%)
Moderate- intensity statin (16 trials)	:	95 890	÷	4.6	3.6 (0.8)	63 (8)	27·2 (4·2)	69.5 (15.3)	25254 (26%)	49877 (80%)†	54879 (57%)	23 818 (25%)
4S² ³	1994	4444	Simvastatin 20-40 mg/day vs placebo	5.4	4·9 (0·7)	59 (7)	26.0 (3.3)	NA	827 (19%)	NA	4444 (100%)	202 (5%)
WOSCOPS ²⁶	1995	6595	Pravastatin 40 mg/day vs placebo	4·8	5.0 (0.5)	55 (6)	26.0 (3.2)	77-8 (12-4)	0	NA	1066 (16%)	143 (2%)
CARE ²⁶	1996	4159	Pravastatin 40 mg/day vs placebo	4.9	3.6 (0.4)	(6) 65	27.6 (4.4)	67.2 (15.7)	576 (14%)	3851 (93%)	4159 (100%)	667 (16%)
	1998	9014	Pravastatin 40 mg/day vs placebo	5.9	3-9 (0-8)	61 (8)	26-8 (3-8)	70.6 (16.3)	1516 (17%)	NA	9014 (100%)	1077 (12%)
LIPS ²²	2002	1677	Fluvastatin 80 mg/day vs placebo	4.0	3·4 (0·8)	60 (10)	26.5 (3.3)	67.6 (15.5)	271 (16%)	1650 (98%)	1677 (100%)	204 (12%)
HPS ²⁴	2002	20536	Simvastatin 40 mg/day vs placebo	5.2	3·4 (0·8)	64 (8)	27.6 (4.4)	72.2 (16.5)	5082 (25%)	19 901 (97%)	17386 (85%)	5973 (29%)
PROSPER ²⁸	2002	5804	Pravastatin 40 mg/day vs placebo	3.3	3·8 (0·8)	75 (3)	26.8 (4.2)	56.7 (13.6)	3000 (52%)	NA	2565 (44%)	760 (13%)
ASCOT-LLA ²⁹	2003	10 2 4 0	Atorvastatin 10 mg/day vs placebo	3.3	3·4 (0·7)	63 (6)	28.6 (4.6)	68.4 (12.9)	1919 (19%)	9687 (95%)	1684 (16%)	2699 (26%)
ALERT ²¹	2003	2102	Fluvastatin 40–80 mg/day vs placebo	5.5	4.1(1.0)	50 (11)	25·8 (4·5)	49.6 (17.0)	715 (34%)	2039 (97%)	409 (19%)	430 (20%)
CARDS ³⁶	2004	2838	Atorvastatin 10 mg/day vs placebo	4.2	2.9 (0.8)	61 (8)	28.8 (3.6)	64.2 (11.3)	909 (32%)	2676 (94%)	106 (4%)	2838 (100%)
4D ³⁵	2005	1255	Atorvastatin 20 mg/day vs placebo	2.7	3.3 (0.8)	66 (8)	27·6 (4·8)	NA	578 (46%)	924 (74%)	1041 (83%)	1255 (100%)
ASPEN ³⁴	2006	2410	Atorvastatin 10 mg/day vs placebo	4.0	2.9 (0.7)	60 (8)	28.9 (3.8)	65.9 (12.8)	811 (34%)	2029 (84%)	747 (31%)	2410 (100%)
CORONA ³⁰	2007	4982	Rosuvastatin 10 mg/day vs placebo	2.7	3.6 (0.9)	72 (7)	26.4 (3.6)	55-4 (15-1)	1175 (24%)	NA	4982 (100%)	1481 (30%)
GISSI-HF ³¹	2008	4574	Rosuvastatin 10 mg/day vs placebo	3.9	3.1 (0.9)	68 (11)	27·1 (4·5)	66.3 (20.4)	1032 (23%)	4574 (100%)	4574 (100%)	1771 (39%)
AURORA ³²	2009	2555	Rosuvastatin 10 mg/day vs placebo	3.9	2.6 (0.9)	64 (9)	24.8 (3.9)	NA	969 (38%)	NA	1025 (40%)	747 (29%)
HOPE-3 ³³	2016	12 705	Rosuvastatin 10 mg/day vs placebo	5.5	3.3 (0.9)	66 (6)	27-1 (4-7)	79-6 (16-1)	5874 (46%)	2546 (20%)	0	1161 (9%)
High-intensity statin (two trials)	:	21 445	:	2.6	2.9 (0.5)	65 (9)	27·6 (4·0)	70·7 (14·6)	8282 (39%)	4415 (93%)†	4731 (22%)	1651 (8%)
SPARCL ¹⁸	2006	4731	Atorvastatin 80 mg/day vs placebo	4.9	3.5 (0.6)	63 (11)	27.9 (5.2)	65.2 (13.8)	1908 (40%)	4415 (93%)	4731 (100%)	909 (19%)
JUPITER ¹⁷	2008	16714	Rosuvastatin 20 mg/day vs placebo	1.9	2.7 (0.5)	65 (8)	27·5 (3·6)	72·3 (14·8)	6374 (38%)	NA	0	742 (4%)
More intensive vs less intensive statin (double blind; four trials)	:	30724	÷	4.9	2.5(0.6)	62 (9)	28.4 (5.1)	72.2 (15.6)	5965 (19%)	28 865 (94%)	30724 (100%)	5340 (17%)
											(Table continu	(Table continues on next page)

	Year of publication of primary results	Number of participants	Treatment comparison	Median follow up, years	Mean LDL cholesterol concen- tration, mmol/L (SD)	Mean age, years (SD)	Mean BMI, kg/m² (SD)	Mean estimated GFR, mL/min per 1-73 m² (SD)	Women, n (%)	White participants, n (%)	Participants with a history of vascular disease, n (%)	Participants with diabetes at baseline, n (%)*
(Continued from previous page) Comparison of moderate- intensity regimens	revious page) 	16561		5.6	2.4 (0.6)	63 (9)	28.0 (4.3)	74-8 (16-8)	3152 (19%)	15 679 (95%)	16561(100%)	2339 (14%)
(two triais) A to Z³7	2004	4497	Simvastatin 40 mg/day then 80 mg/day vs placebo then simvastatin 20 mg/day	2.0	2.1 (0.5)	60 (11)	27.6 (4.8)	68-4 (16-0)	1100 (24%)	3825 (85%)	4497 (100%)	1059 (24%)
SEARCH ³⁸	2010	12 064	Simvastatin 80 mg/day vs 20 mg/day	7.0	2.5 (0.6)	64 (9)	28.1 (4.1)	77.2 (17.1)	2052 (17%)	11854 (98%)	12064 (100%)	1280 (11%)
Comparison of high-intensity vs moderate- intensity regimens (two trials)	:	14163	:	4.1	2.5 (0.6)	60 (10)	29.0 (6.0)	69.1 (14.3)	2813 (20%)	13 186 (93%)	14163 (100%)	3001 (21%)
PROVE-IT ³⁹	2004	4162	Atorvastatin 80 mg/day vs pravastatin 40 mg/day	2.1	2.6 (0.7)	58 (11)	29.5 (5.7)	78.8 (18.7)	911 (22%)	3776 (91%)	4162 (100%)	1034 (25%)
TNT ⁴⁰ All +riale	2005		Atorvastatin 80 mg/day vs 10 mg/day		2.5 (0.5)	(61 (9) 62 (8)	28-8 (6-1) 27-E (4-2)	65-0 (12-4) 70-1 (15-1)	1902 (19%) (2007 (19%)	9410 (94%) 80.017 (85%)+	10 001 (100%)	1967 (20%)
All trials hall excludes 65 partit rail excludes 65 partit tudy. AFCAP5/TexCA revention of Coronal revention of the tudy. "Baseline diaba f assignment to a tre	 in a 1:1 allocation (cipants for whorr APS=Air Force/Tes by Heart Disease f is C.ARDS=Collabo is C.ARDS=Collabo : C.ARDS=Collabo : C.ARDS=Collabo : J. Artenic Disease. I the sis defined as so the sis defined as so atment group. 1f	154 bo4 - Some participan oldata were not av cas Coronary Athe Endpoints in Non- rative Atorovas tati art Outcomes Pre- art Outcomes Pre- Additional Reduct participants with Percentages were	All trials andomised in a 1.1 allocation. Some participants in the AURORA (n=218), CORONA (n=27), and JUPTER (n=1088) trials withdrew consent for use of their data after the trial, and hence data from these participants is excluded. The ASCOT-LLA trial excluded for a trial value and tax were not available due to protocol violations, and so are not included in the number of participants or percentages shown. 4D=Die Deutsche Diabetes Dialyes Studie. 45–Scandinavian Simvastatin Study for Prevention of Coronary Atherosderosis Prevention Study. ALERT=Assessment of Lescol in Renal Transplantation. ASCOT-LLA=Angio-Scandinavian Cardia Coutcomes Trial-Lipid Lowering Arm. ASPEN=Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus. A to Z=Aggrastat to Zocor. AURORA=A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events. CARDS=Collaborative Atorvastatin Diabetes Study. CARE=Cholesterol And Recurrent Events. CORONA=Controlled Rosuvastatin in Isubjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events. CARDS=Collaborative Atorvastatin Diabetes Study. CARE=Cholesterol And Recurrent Events. CORONA=Controlled Rosuvastatin in Istheam Cardia Coutcomes Prevention Events. CARDS=Collaborative Atorvastatin Diabetes Study. CARE=Cholesterol And Recurrent Events. CORONA=Controlled Rosuvastatin in Istheam Cardia Coutcomes Prevention Frail. HPS-Heart Protection Study. JUPTIR=Justification for the Use of Rosuvastatin in Istheam Cutcomes Prevention Prevention Prevention Rougy. JUPTIR=Justification for the Use of Rosuvastatin in Istheam Cutcomes Prevention Rougy. JUPTIR=Justification for the Use of Rosuvastatin in Intervention Prevention Prevention Rougy. JUPTIR=Justification for the Use of Rosuvestatin in Rotustention Prevention Rougy. JUPTIR=Justification for the Use of Rosuvestatin in Intervention Prevention Prevention Rougy. JUPTIR=Justification for the Use of Rosuvestatin	4.4 7), and JUPI 7), and JUPI 7), and JUPI section 5104 2.2 Aggrasti Recurrent Ev Recurrent Ev ARCL=Strok Mere inforr	3:3 (U-7) IER (n=1088) t ded in the num es col in Renal T ents. CORONA, Y. JUPITER=Just Y. JUPITER=Just PROSPORTIVE 3 f as having diah b as having diah b as having diah b as having diah b	b3 (8) trials withdreads withdreads withdreads for cansplantation annovable and stur- canson for trification for Study of Prava y Aggressive petes at basel and ethnicit	2/-5 (4-3) ew consent for us cipants or percent ion. ASCOT-LLA=, udy to Evaluate th Rosuvastatin ML the Use of Statin vastatin in the Ek eleuction in the basis v sine on the basis v	/0.1 (1.c.(1) te of their data afte tages shown. 4D=1 Anglo-Scandinavia ne Use of Rosuvasta ne Use of Rosuvasta is in Prevention: ar derly at Risk PROV derly at Risk PROV of adverse events, ked (the relevant de	40.438 (20%) ar the trial, and henc Die Deutsche Diabele an Cardiac Outcome atin in Subjects on R Heart Failure. GISSI In Intervention Trial I fe.TT-Pravastatin or fe.TT-Pravastatin or glucose-lowering to New	59 01/ (85%)T edata from these pa tes Dialyse Studie. 45 tes Dialyse Studie. 45 tes Ualartial-Lupid Lowerin, Revulating Rosuvasta Attorvastatin Evaluai Attorvastatin Evaluai Attorvastatin cyalucos ratione 73 832 for all	90.334 (58%) articipants is exclude 5-5-candinavian Sim g Arm. ASPEN=Aton g Arm. ASPEN=Aton g Arm. ASPEN=Aton artin. LIPID=Long-te atin. LIPID=Long-te tition and Infection T =West of Scotland C. e or HbA ₄ , measurer (Itrials of statin vs pk	J1041 (20%) ed. The ASCOT-LL wastatin Survival rvastatin Survival rvastatin Study fo Sopravvivenza m Intervention herapy. nonany Preventio acebo, 62496 for

Table: Characteristics of the participating trials

	Events (% per	annum)	Observed	-expected		Rate ratio (CI)
	Statin	Placebo	о-е	var(o-e)		
Low-intensity or moderate-intensity statin	(n=39179)	(n=39266)				
Diabetes-related adverse events	1224 (0.7)	1153 (0.6)	32.3	594·1		1·06 (99% Cl 0·95–1·17)
Diabetes determined from co-medication	764 (0.4)	680 (0.4)	40.2	357.0	⊢ ∎−	1·12 (99% CI 0·98–1·28)
Subtotal: diabetes-related adverse events and co-medication	1523 (0.8)	1396 (0.8)	60.3	728.6	\diamond	1·09 (95% Cl 1·01–1·17)
Biochemically determined diabetes	1497 (0.8)	1369 (0.8)	67.7	715.8	-0-	1·10 (99% Cl 1·00–1·21)
Any new-onset diabetes	2420 (1·3)	2214 (1.2)	106.8	1156.8	\diamond	1·10 (95% Cl 1·04–1·16)
High-intensity statin	(n=9935)	(n=9859)				
Diabetes-related adverse events	246 (0.9)	174 (0.7)	37.0	105.0	_	1·42 (99% Cl 1·11–1·83)
Diabetes determined from co-medication	198 (0.8)	159 (0.6)	20.1	89.2		1·25 (99% Cl 0·95–1·64
Subtotal: diabetes-related adverse events and co-medication	297 (1·1)	229 (0·9)	35.1	131.5	\Leftrightarrow	1·31 (95% Cl 1·10–1·55)
Biochemically determined diabetes	1078 (4.1)	788 (3.0)	149.3	465.7	-0-	1·38 (99% Cl 1·22–1·55)
Any new-onset diabetes	1221 (4.8)	905 (3.5)	163.9	530.8		1·36 (95% Cl 1·25–1·48
				0	·80 1·00 1·25 1·50 2·0	00
				Favours	statin Favours placebo	

Figure 1: Effect of statin vs placebo on new-onset diabetes by statin intensity

Test for heterogeneity between low-intensity or moderate-intensity and high-intensity regimens for the outcome of any new-onset diabetes (p<0.0001). Var(o-e) represents the variance of the log-rank observed-minus-expected statistic.

Overall, at a given level of statin intensity, the relative effects on new-onset diabetes did not vary much in different types of participants (eg, by age, sex, race or ethnicity, history of vascular disease, BMI, eGFR, quartiles of glycaemia, diabetes risk score, and lipid characteristics; appendix pp 19–24), between statins (appendix p 15), or over time (appendix pp 25–26). In particular, the RRs for new-onset diabetes were similar among quartiles of baseline glycaemia and quartiles of baseline-defined risk of new-onset diabetes (appendix pp 19, 21). They were also similar when RRs were weighted for absolute differences in LDL cholesterol at 1 year between trials (low-intensity or moderate-intensity statin versus placebo, RR 1·09, 95% CI 1·03–1·15; highintensity statin versus placebo, 1·31, 1·21–1·41).

In the trials of statin versus placebo, glucose concentrations were recorded systematically at baseline and follow-up among all people without diabetes in seven trials and HbA_{1c} values were recorded in this way in two trials (appendix p 2). The mean increase in glucose concentration during the treatment period compared with participants assigned to receive placebo was 0.04 mmol/L for both low-intensity or moderateintensity (95% CI 0.03–0.05) and high-intensity statin therapy (0.02–0.06), and the corresponding increases in HbA_{1c} values were 0.06% (0.00–0.12) for lowintensity or moderate-intensity and 0.08% (0.07–0.09) for high-intensity statin therapy (appendix p 10).

The annual rate of development of new-onset diabetes in the placebo group was substantially greater in higher versus lower quartiles of baseline glycaemia. Consequently, the majority (ie, approximately 62%) of excess cases of new-onset diabetes occurred among participants in the highest quarter of the baseline glycaemia distribution for both low-intensity or moderateintensity and high-intensity statin therapy (figure 2). The proportion of excess cases in the top quarter increased only slightly to approximately 67% when baseline age, sex, BMI, triglycerides, eGFR, and HDL cholesterol were added to glycaemia in a diabetes risk score (figure 2).

Among people with diabetes at baseline, allocation to low-intensity or moderate-intensity statin resulted in a 10% relative increase in worsening glycaemia compared with placebo (6224 of 12109 participants assigned to statin therapy [16.3% per year] vs 5902 of 11941 participants assigned to placebo [15.4% per year]; RR 1.10 [95% CI 1.06 to 1.14]; absolute annual excess 1.49% [0.87 to 2.13]), and in the high-intensity trials, allocation to this group resulted in a 24% relative increase in worsening glycaemia (338 of 805 participants assigned to statin therapy [16.0% per year]vs 295 of 846 participants assigned to placebo [12.8% per year]; $1 \cdot 24$ [$1 \cdot 06$ to $1 \cdot 44$]; absolute annual excess $3 \cdot 02\%$ [0.73 to 5.69]; figure 3). In the trials of low-intensity or moderate-intensity statin versus placebo and the trials of more versus less intensive statin versus placebo, the relative effects on worsening glycaemia were larger in the earlier than later years of follow-up (appendix pp 26-27). The mean increase in glucose concentration during the treatment period compared with participants assigned to receive placebo was 0.12 mmol/L (95% CI 0.04 to 0.21) for low-intensity or moderate-intensity statin therapy and $0\!\cdot\!22$ mmol/L (–0.02 to 0.45) for high-intensity statin therapy, and the corresponding increases in HbA_{lc} were $0{\cdot}09\%$ (0{\cdot}05 to 0{\cdot}14) for low-intensity or moderateintensity statin therapy and 0.24% (0.09 to 0.38) for highintensity statin therapy (appendix p 10).

12 placebo-controlled trials recorded at least one measure of bodyweight in participants without diabetes after assignment to a treatment group. In these




Figure 2: Absolute excess rates of new-onset diabetes in trials of statin versus placebo

Rates are shown by quartile of glycaemia (A) and quartile of predicted 5-year risk of new-onset diabetes (B) for low-intensity or moderate-intensity statins and by quartile of glycaemia (C) and quartile of predicted 5-year risk of new-onset diabetes (D) for high-intensity statins. The rate ratio for each group at a specific level of intensity is assumed to be constant. Mean HbA₁₂ for group 1 of glycaemia is 5-72%, for group 2 of glycaemia is 5-51%, for group 3 of glycaemia is 5-80%, and for group 4 of glycaemia is 6-17% for low-intensity or moderate-intensity therapy. Mean HbA₁₂ for group 1 of glycaemia is 5-51%, for group 2 is 5-51%, for group 2 is 5-51%, for group 2 is 5-51%, for group 3 is 5-79%, and for group 4 is 6-14% for high-intensity therapy. Details of the risk score for new-onset diabetes are described in the methods and in the appendix (p 28). Individuals were categorised into four equally sized groups of predicted 5-year risk of new-onset diabetes: <2-9% (group 1), 2-9% to <5-7% (group 2), 5-7% to <11-5% (group 3), and $\ge 11-5\%$ (group 4).

participants, the mean baseline weight was 78.14 kg (SD 14.67), and allocation to statin therapy resulted in an increase of 0.16 kg (95% CI 0.08 to 0.24) at 1 year and 0.30 kg (0.22 to 0.37) at the final measurement (appendix p 11) compared with placebo. 11 placebo-controlled trials recorded at least one measure of

bodyweight in participants with diabetes after assignment to a treatment group. In these participants, the mean baseline weight was $81 \cdot 27 \text{ kg}$ (SD $14 \cdot 61$), and allocation to statin therapy resulted in an increase of $0 \cdot 02 \text{ kg}$ ($-0 \cdot 10 \text{ to } 0 \cdot 14$) at 1 year and $0 \cdot 04 \text{ kg}$ ($-0 \cdot 15 \text{ to}$ $0 \cdot 23$) at the final measurement compared with placebo.

	Events (% per	annum)	Observed	-expected		Rate ratio (CI)
	Statin	Placebo	o-e	var(o-e)		
Low-intensity or moderate-intensity statin	(n=12109)	(n=11941)				
Ketosis or glucose control complications	308 (0.6)	299 (0.6)	2.2	151·7	_	1·01 (99% Cl 0·82–1·25
Worsening HbA _{1c}	2732 (6.4)	2484 (5.9)	181.8	1284·2		1·15 (99% Cl 1·07–1·24
Escalation of diabetes co-medication	4081 (9·3)	3924 (9.0)	100.9	1680.4		1·06 (99% Cl 1·00–1·13
Any worsening glycaemia	6224 (16·3)	5902 (15·4)	252.5	2737.5	\diamond	1·10 (95% Cl 1·06–1·14
High-intensity statin	(n=805)	(n=846)				
Ketosis or glucose control complications	7 (0·3)	5 (0.2)	1.1	3.0	← →	1·42 (99% CI 0·32–6·30
Worsening HbA _{1c}	108 (3.9)	78 (2.7)	20.2	45.8		1·55 (99% Cl 1·06–2·27
Escalation of diabetes co-medication	254 (11·9)	231 (10.0)	20.5	120.8		1·18 (99% CI 0·94–1·50
Any worsening glycaemia	338 (16.0)	295 (12.8)	33·3	157·2	\sim	1·24 (95% Cl 1·06–1·44
				- Faugur	0.80 1.00 1.25 2.00	

Figure 3: Effect of statin vs placebo on worsening glycaemia by statin intensity

Test for heterogeneity between low-intensity or moderate-intensity and high-intensity regimens for the outcome of any worsening glycaemia (p=0.15). Var(o-e) represents the variance of the log-rank observed-minus-expected statistic.

Discussion

This meta-analysis advances our understanding of the adverse effects of statin therapy on diabetes. The results show that statin therapy causes a moderate dose-dependent increase in new diagnoses of diabetes, that most of the excess of new-onset diabetes occurs among individuals who are already at high risk of diabetes (ie, their plasma markers of glycaemia are close to the diagnostic threshold for diabetes), and that new-onset diabetes in these individuals is likely to be explained by small statin-induced increases in markers of glycaemia (ie, plasma glucose and HbA_{tc}). The relative effects on worsening glycaemic control in people with known diabetes largely mirrored those for new-onset diabetes.

The JUPITER trial was the first large randomised trial of statin therapy to report a significant increase in the risk of incident diabetes (270 participants assigned to receive 20 mg rosuvastatin vs 216 participants assigned to receive placebo; p=0.01; corresponding to a 25% proportional increase in physician-diagnosed diabetes for participants in the rosuvastatin group).17 More recently, the REPRIEVE trial reported a higher rate of incident diabetes in participants assigned to receive 4 mg pitavastatin daily compared with placebo (RR 1.35, 95% CI 1.09-1.66).⁴¹ Atorvastatin has also been reported to induce a small increase in blood glycaemia within a few months of starting treatment, both in people without diabetes⁴² and in those with diabetes.⁴³ Small population-wide shifts in blood glycaemia (of the magnitude seen in our analyses) can have a large relative effect on the proportion of a population exceeding a diagnostic threshold level near the tail of the distribution (figure 4), as evidenced by other drugs that produce small changes in glycaemia but result in moderately large relative changes in the risk of diabetes. For example, in the Diabetes Prevention Program trial, allocation to metformin reduced HbA_{1c} by approximately 0.1% and also reduced the risk of diabetes by 31%

compared with placebo,⁴⁵ and in the dal-OUTCOMES trial, which studied dalcetrapib, a reduction in HbA_{1c} of a similar size resulted in approximately 23% reduction in risk compared with placebo.⁴⁶

Overall, there was little availability of data from postrandomisation glycaemic measures among people without known diabetes (appendix p 2). This scarcity was particularly true for HbA1c, which was recorded systematically at baseline and at least once during followup among all people without diabetes in only two trials of statin versus placebo (GISSI-HF trial of low-intensity or moderate-intensity statin therapy³¹ [mean baseline HbA_{1c} 5.5%]; JUPITER trial of high-intensity statin therapy¹⁷ [mean baseline HbA_{1c} 5.7%]; appendix p 9). The paucity of HbA_{1c} data is not surprising because HbA_{1c} did not become a widely recognised diabetes diagnostic marker until 2011,¹⁴ which was after the inception of all trials included in our analyses. Additionally, it was not always possible to reliably ascertain whether glucose concentration was measured in a fasting or non-fasting state. Given these caveats, to allow for systematic differences in data capture between trials and ensure that the absolute excess rates of new-onset diabetes between trials were comparable, we analysed the excess rates excluding diagnoses made with biochemical measures of glycaemia alone. When this exclusion was made, the RRs overall for low-intensity or moderate-intensity and high-intensity statin therapy were similar to when such biochemical measures were included (figure 1).

In the high-intensity statin trials, the event rate for the development of new-onset diabetes was substantially higher in both the intervention and placebo groups than that seen in the low-intensity or moderate-intensity statin trials. This higher rate was driven by a greater proportion of trial participants in the high-intensity statin trials, particularly in the JUPITER trial, having at least one follow-up HbA_{ic} measurement. Biochemically determined diabetes rates were 3.0% per annum for

high-intensity trials and 0.8% for low-intensity or moderate-intensity therapy trials in the placebo groups, whereas rates of diabetes determined by reports of diabetes-related adverse events and use of glucoselowering medication in the placebo groups for the same groups of trials were similar (figure 1). This finding indicates that, although the relative excesses of new-onset diabetes observed for low-intensity or moderate-intensity statin versus placebo and high-intensity statin versus placebo are likely to be robust and generalisable, the differences in absolute excesses of diagnoses of diabetes between these two groups of trials were determined predominantly by the proportion of trial participants for whom a biochemical diagnosis was made solely through an HbA_{te} measurement after randomisation. In practice, such measurements might not be obtained routinely in people without diabetes, but it is likely that the rate of diagnosis of diabetes would be higher than it currently is if such a practice was widely adopted.

The RRs for new-onset diabetes did not vary significantly over time. We hypothesise that the reason for this finding is that, in each successive year of follow-up, a new group of people becomes at risk of exceeding the diagnostic threshold for diabetes because of an agerelated increase in glycaemia, and those taking a statin will be slightly more likely to do so. For high-intensity statin therapy, the absolute rates were observed to be greater for JUPITER compared with SPARCL, particularly when biochemical measurements of glycaemia were included as a diagnostic criterion (appendix p 16). By contrast, among people with a known diagnosis of diabetes at baseline, the early excess of worsening glycaemia with a statin did not persist in the long term (appendix pp 26-27), perhaps because glycaemic control is typically monitored in such individuals and likely to be managed.

Previous scientific literature has suggested that the increased risk of diabetes caused by statin therapy might be partly due to an increase in bodyweight, which in turn increases diabetes risk.47 Data from several trials and meta-analyses have provided an indication of the probable association between bodyweight and diabetes. In the DPP trial, among 3234 individuals without diabetes, lifestyle intervention reduced bodyweight by 5.6 kg and was associated with a 58% (95% CI 48 to 66) reduction in the incidence of type 2 diabetes.45 Evidence also exists from meta-analyses of randomised controlled trials of lifestyle interventions for diabetes prevention: in one analysis, compared with usual treatment, a mean bodyweight reduction of 2.45 kg (95% CI -3.56 to -1.33) was associated with a 37% (0.51 to 0.79) reduction in progression to type 2 diabetes at 3 years.48 The observed increase in bodyweight due to statin therapy in participants without diabetes in our analyses (ie, 0.30 kg at final measurement; appendix p 11) was much smaller than in these studies. It therefore seems implausible that such a small change in bodyweight would explain more




Figure 4: Examples of the effects of population-wide upwards shifts in mean HbA.,

Effects of population-wide upwards shifts of 0.05% (A) or 0.10% (B) in mean HbA_{1c} on the proportion above the threshold level of 6.50%. We assumed a normal distribution of HbA_{1c} with a mean of 5.50% (SD 0.60). The SD is taken from the UK Biobank population.⁴⁴ AUC=area under the curve.

than a small proportion of the observed increase in diagnoses of diabetes due to statin therapy.

A comparison of the cardiovascular benefits and risks of diabetes from statin therapy based on the results of the JUPITER trial⁴⁹ previously concluded that the cardiovascular benefits of rosuvastatin greatly outweighed the risks of new-onset diabetes, despite this trial being conducted in a primary prevention setting among apparently healthy people (without hyperlipidaemia but with increased concentration of CRP on a high-sensitivity CRP test). Notably, vascular benefits of statin therapy represent the net effect of the aggregate effects of statins on blood lipids and glycaemia, such that any theoretical adverse effects of statins on cardiovascular risk that might arise from small increases in glycaemia (or, indeed, from any other mechanism) are already accounted for in the overall reduction in cardiovascular risk that is seen with statin therapy in these trials. Furthermore, the risk of future new major vascular events is significantly greater following major vascular events than following a diagnosis of diabetes.50,51 It was not possible to assess clinically significant microvascular complications of diabetes in our analyses both because of the absence of longer-term adverse event data (since development of such complications typically requires many years of exposure to poor glycaemic control) and the absence of any consistent detailed diagnostic information (eg, retinal photographs and measures of microalbuminuria or proteinuria). However, in a meta-analysis of randomised controlled trials comparing less intensive with more intensive glucose control, there was a 20% relative increase in risk of clinically significant renal complications (absolute excess risk 0.4% per year) and a 13% relative increase in risk of clinically significant retinal complications (absolute excess risk 0.2% per year) due to exposure to 0.9% higher HbA_{1c} over 5 years in major diabetes trials, ⁵² so the changes induced by a statin are likely to be too small to result in a material change in the risk of microvascular disease in people with diabetes.

Our findings have several implications for clinical practice. First, our findings make clear that the majority of new diagnoses of diabetes resulting from statin therapy will occur among people who are already close to the biochemical diagnostic threshold for diabetes. In our study, approximately 62% of cases of new-onset diabetes attributable to statin therapy occurred among individuals in the top quarter of the glycaemia distribution, and adding other risk factors to glycaemia resulted in only a modest increase (to approximately 67%) in the proportion of cases attributable to statin therapy than for glycaemia alone. Our findings also imply that, since the effect of statin therapy on measures of glycaemia within an individual is small (ie, considerably smaller than the combined variation of within-individual53 and laboratory analytical variation54), there is likely to be little clinical benefit in measuring glucose concentrations and HbA_{1c} values routinely after starting statin therapy with the aim of making comparisons to values taken before the initiation of a statin. However, people should continue to be screened for diabetes and associated risk factors and have their glycaemic control monitored in accordance with current clinical guidelines.

Although our study emphasises the effects of various statin regimens on the risk of a new diagnosis of diabetes, it does have some limitations. The most important of these limitations is that most of the included trials were not principally designed to test a hypothesis of the effects of statin therapy on diabetes. As aforementioned, one consequence of this was a paucity of data for measures of glycaemia among those without diabetes. Event rates for cases resulting from measurement of fasting plasma glucose might have been overestimated if participants did not fast, although the absolute differences between active and placebo groups would not be materially biased, and exclusion of cases of biochemically determined diabetes did not substantially affect findings. Moreover, cases of diabetes in our analysis were constructed by use of trial data, and we were unable to assess type of diabetes, but we expect that the vast majority of cases in participants of the age included in the trials would have been type 2 diabetes. Very occasionally, glucose-lowering medication might have been used for an indication other than diabetes, and although we were able to count initiation and escalation of diabetes treatment, we were not able to analyse any changes in doses of these medications. The intention-to-treat analyses of the effects of allocation to statin therapy in this meta-analysis preserve the

randomised comparisons within each trial, but might of course result in some underestimation of the full effects of taking statin therapy in the long term. Additionally, some data were unavailable for our analyses: data from 218 (8.5%) of 2555 participants in the AURORA trial,³² 27 (0.5%) of 4982 participants in the CORONA trial,³⁰ and 1088 (6.5%) of 16714 participants in the JUPITER¹⁷ trial were not provided because of data privacy concerns. However, it is unlikely that missing data would have affected our main conclusions.

Among people without diabetes, statin therapy produces a dose-dependent increase in the rate of diagnosis of diabetes by inducing a very small increase in glycaemia. People are most at risk of exceeding the diagnostic threshold for diabetes due to statin therapy if their glycaemic control is close to the threshold before treatment. The diabetes-related risks arising from the small changes in glycaemia resulting from statin therapy are greatly outweighed by the benefits of statins on major vascular events when the direct clinical consequences of these outcomes are taken into consideration.

CTT Collaboration

Writing committee: Christina Reith*, David Preiss*, Lisa Blackwell, Jonathan Emberson, Enti Spata, Kelly Davies, Heather Halls, Charlie Harper, Lisa Holland, Kate Wilson, Alistair J Roddick, Christopher P Cannon, Robert Clarke, Helen M Colhoun, Paul N Durrington, Shinya Goto, Graham A Hitman, G Kees Hovingh, J Wouter Jukema, Wolfgang Koenig, Ian Marschner, Borislava Mihaylova, Connie Newman, Jeffrey L Probstfield, Paul M Ridker, Marc S Sabatine, Naveed Sattar, Gregory G Schwartz, Luigi Tavazzi, Andrew Tonkin, Stella Trompet, Harvey White, Salim Yusuf, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent.

*Joint first authors.

CTT secretariat: Jane Armitage, Colin Baigent, Elizabeth Barnes, Lisa Blackwell, Rory Collins, Kelly Davies, Jonathan Emberson, Jordan Fulcher, Heather Halls, William G Herrington, Lisa Holland, Anthony Keech, Adrienne Kirby, Borislava Mihaylova, Rachel O'Connell, David Preiss, Christina Reith, John Simes, Kate Wilson. CTT collaborating trialists: A to Z trial (phase Z) Michael Blazing, Eugene Braunwald, James de Lemos, Sabina Murphy; Terje R Pedersen, Marc Pfeffer, Harvey White, Stephen Wiviott. AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study) Michael Clearfield, John R Downs, Antonio Gotto Jr, Stephen Weis. ALERT (Assessment of Lescol in Renal Transplantation) Bengt Fellström, Hallvard Holdaas (deceased), Alan Jardine, Terje R Pedersen. ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) David Gordon, Barry Davis, Curt Furberg, Richard Grimm, Sara Pressel, Jeffrey L Probstfield, Mahboob Rahman, Lara Simpson. ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events) Michael Koren. ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Bjorn Dahlöf, Ajay Gupta, Neil Poulter, Peter Sever, Hans Wedel. ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus) Robert H Knopp (deceased). AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects On Regular Haemodialysis: an Assessment of Survival and Cardiovascular Events) Stuart Cobbe, Bengt Fellström, Hallvard Holdaas (deceased), Alan Jardine, Roland Schmieder, Faiez Zannad. CARDS (Collaborative Atorvastatin Diabetes Study) D John Betteridge (deceased), Helen M Colhoun, Paul N Durrington, John Fuller (deceased), Graham A Hitman, Andrew Neil, CARE (Cholesterol And Recurrent Events Study) Eugene Braunwald, Barry Davis, C Morton Hawkins, Lemuel Moyé (deceased), Marc Pfeffer, Frank Sacks. CORONA

(Controlled Rosuvastatin Multinational Trial in Heart Failure) John Kjekshus, Hans Wedel, John Wikstrand. 4D (Die Deutsche Diabetes Dialyse Studie) Christoph Wanner, Vera Krane. GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico) Heart Failure and Prevention trials Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Aldo Maggioni, Roberto Marchioli, Enrico B Nicolis, Luigi Tavazzi, Gianni Tognoni. HOPE-3 Jackie Bosch, Eva Lonn, Salim Yusuf. HPS (Heart Protection Study) Jane Armitage, Louise Bowman, Rory Collins, Anthony Keech, Martin Landray, Sarah Parish, Richard Peto, Peter Sleight (deceased). IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid-lowering) John J P Kastelein, Terje R Pedersen. JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Robert Glynn, Antonio Gotto Jr, John J P Kastelein, Wolfgang Koenig, Jean MacFadyen, Paul M Ridker. LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) Anthony Keech, Stephen MacMahon, Ian Marschner, Andrew Tonkin, John Shaw (deceased), John Simes, Harvey White. LIPS (Lescol Intervention Prevention Study) Patrick W Serruys. Post-CABG (Post-Coronary Artery Bypass Graft Study) Genell Knatterud (deceased). PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) Gerard J Blauw, Stuart Cobbe, Ian Ford, Peter Macfarlane, Chris Packard, Naveed Sattar, James Shepherd (deceased), Stella Trompet. PROVE-IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy) Eugene Braunwald, Christopher P Cannon, Sabina Murphy. SEARCH (Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine) Rory Collins, Jane Armitage, Louise Bowman, Richard Bulbulia, Richard Haynes, Sarah Parish, Richard Peto, Peter Sleight (deceased). SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Pierre Amarenco. K Michael Welch, 4S (Scandinavian Simvastatin Survival Study) John Kjekshus, Terje R Pedersen, Lars Wilhelmsen. TNT (Treating to New Targets) Philip Barter, Antonio Gotto Jr, John LaRosa, John J P Kastelein, James Shepherd (deceased). WOSCOPS (West of Scotland Coronary Prevention Study) Stuart Cobbe, Ian Ford, Sharon Kean, Peter Macfarlane, Chris Packard, Michele Robertson, Naveed Sattar, James Shepherd (deceased), Robin Young. Other CTT members: Hiroyuki Arashi, Robert Clarke, Marcus Flather, Shinya Goto, Uri Goldbourt, Jemma Hopewell, G Kees Hovingh, George Kitas, Connie Newman, Marc S Sabatine, Gregory G Schwartz, Liam Smeeth, Jonathan Tobert, John Varigos, Junichi Yamaguchi. Independent oversight committee: Emily Banks, Michael Blastland, Stephen Evans, Robert Temple, Peter Weissberg (chair), Janet Wittes.

Contributors

The writing committee accepts full responsibility for the content of this paper. Conceived and designed the experiments: JA, CB, LB, RCo, KD, JE, HH, LH, AK, DP, CR, ES, JS, and KW. Access to, collection of, and verification of raw data: CB, LB, KD, JE, CH, HH, LH, CR, ES, and KW. Analysed the data: JA, CB, LB, RCo, KD, JE, CH, HH, LH, DP, AJR, CR, ES, and KW. Wrote the initial draft of the paper: CR, DP, LB, JE, and CB. Final responsibility for decision to submit for publication: CR, DP, and CB. Critical revision of manuscript for important intellectual content: all authors. All collaborators had an opportunity to contribute to the interpretation of the results and to drafting of the report. All authors of the writing committee had final responsibility for the decision to submit for publication.

Declaration of interests

CR, DP, LB, JE, KD, HH, CH, LH, KW, AJR, RCl, BM, JA, CB, and RCo are affiliated with the Nuffield Department of Population Health, which has an explicit policy of not accepting any personal honoraria payments directly or indirectly from the pharmaceutical and food industries. It only seeks reimbursement to the University of Oxford for the costs of travel and accommodation to participate in scientific meetings (https://www.ndph.ox.ac.uk/about/independence-of-research). CR reports receiving funding to the University of Oxford from the UK National Institute for Health and Care Research Health Technology Assessment (NIHR HTA) Programme (17/140/02) and holding unpaid roles on the Clinical Data Interchange Standards Consortium (CDISC) as a board member and WHO as a scientific advisor. DP reports receiving funding to his research institution (but no personal funding) from Novartis for the ORION 4 trial of inclisiran, Novo Nordisk for the ASCEND PLUS trial of semaglutide, and Boehringer Ingelheim and Eli Lilly for the EMPA-KIDNEY trial and being a committee member for National Institute for Health and Care Excellence guideline NG238 (cardiovascular disease: risk assessment and reduction including lipid modification guideline). LB reports being an unpaid CDISC Expert Advisory Board member. AJR reports funding to his research institution from Boehringer Ingelheim and Eli Lilly for the EMPA-KIDNEY trial. ES reports now being an employee of AstraZeneca. CPC reports research grants from Bristol-Myers Squibb to his institution for the PROVE IT-TIMI 22 trial; further grants from Amgen, Better Therapeutics, Boehringer-Ingelheim, Daiichi Sankyo, Merck, Novo Nordisk, and Pfizer; receiving consulting fees from Amryt/Chiesi, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, Eli Lilly, Janssen, Lexicon, Merck, Milestone, Pfizer, Rhoshan, and Sanofi; and participating on data safety monitoring boards (DSMBs) or advisory boards for Applied Therapeutics, Areteia, Novo Nordisk, and the Veterans Administration. HMC reports grants from IQVIA, Juvenile Diabetes Research Foundation, Chief Scientist Office, Diabetes UK, the Medical Research Council (UK Research and Innovation), and the EU Commission; taking part in speaker's bureau at Novo Nordisk; being on advisory boards for Novo Nordisk and Bayer; and being a shareholder in Roche Pharmaceuticals and Bayer, GAH reports funding from Pfizer for the CARDS study. GKH reports research grants from Klinkerpad fonds and the Dutch Science Organisation (Vidi); part-time employment with Novo Nordisk; and owning stock options in Novo Nordisk. JWJ reports departmental research grants from and being a speaker (with or without lecture fees) for meetings supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare, Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, the Netherlands Heart Foundation, CardioVascular Research the Netherlands, the Netherlands Heart Institute, and the European Community Framework KP7 Programme. WK reports grants and provision of reagents to his institution from Singulex, Dr Beckmann Pharma, Abbott, and Roche Diagnostics; receiving consulting fees from AstraZeneca, Novartis, Amgen, Pfizer, The Medicines Company, DalCor Pharmaceuticals, Kowa, Corvidia Therapeutics, OMEICOS, Daichii Sankyo, Novo Nordisk, New Amsterdam Pharma, TenSixteen Bio, Esperion, and Genentech; and lecturing fees from Bristol Myers Squibb, Novartis, Amgen, Berlin-Chemie, Sanofi, and AstraZeneca. IM reports funding to his institution from the National Health and Medical Research Council (NHMRC) of Australia and the Medical Research Future Fund of Australia; receiving royalties from Taylor and Francis publishers for authorship of a textbook; payment to his institution for his expert opinion and educational events from the Therapeutic Goods Administration of Australia; and holding several unpaid DSMB memberships for academic trials. BM reports funding to the University of Oxford from the UK NIHR HTA Programme (17/140/02) and being on the Value in Health Advisory Board, the European Society of Cardiology Clinical Practice Guidelines Committee, and the NIHR Programme Grants for Applied Research subpanel A and NIHR Research for Patient Benefit Methodologists Committee A. CN reports textbook royalties from Elsevier; a one-time honorarium for serving on the Steering Committee of Lipid Center of excellence from Medscape; support for registration from the Endocrine Society; travel expenses for the US Food and Deug Administration Endocrine and Metabolic Drugs Advisory Committee; and being unpaid Vice President to the Medical Women's International Association. PMR reports research grant funding to his institution from AstraZeneca, National Heart, Lung, and Blood Institute, Kowa, Novartis, Pfizer, Esperion, and Novo Nordisk; consulting fees from AstraZeneca, Novartis, Novo Nordisk, Janssen, Flame, Agepha, Ardelyx, Zomagen, Horizon Therapeutics, CSL Behring, Cardio Therapeutics, Civi Biopharm, GlaxoSmithKline, SOCAR, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer-Ingelheim, RTI, and Cytokinetics; roles in the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA); and stock or stock options with Uppton, Bitteroot Bio, and Angiowave. MSS reports research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos

Therapeutics, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Eisai, Intarcia, Ionis, Merck, Novartis, Pfizer, Saghmos Therapeutics, and Verve Therapeutics; consulting fees from Amgen, Anthos Therapeutics, AstraZeneca, Beren Therapeutics, Boehringer Ingelheim, Dr Reddy's Laboratories, Fibrogen, Intarcia, Merck, Moderna, Novo Nordisk, Precision BioSciences, and Silence Therapeutics; and being a member of the Thrombolysis in Myocardial Infarction Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abiomed, ARCA Biopharma, Janssen Research and Development, MedImmune, Regeneron Pharmaceuticals, Roche, Siemens Healthcare Diagnostics, Softcell Medical, The Medicines Company, and Zora Biosciences. NS reports grants paid to his institution from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics; consulting fees paid via his institution from Abbott Laboratories Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novo Nordisk, Pfizer, and Sanofi; personal fees from Merck Sharp and Dohme, Novartis, Roche Diagnostics, and Novo Nordisk; and other payment or honoraria paid via his institution from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Janssen. GGS reports grants for research support to the University of Colorado from AstraZeneca, Sanofi, Silence Therapeutics, and The Medicines Company; research support from the US Department of Veterans Affairs; and support to attend trial steering Committee meetings from the University of Oxford. LT reports consulting fees from Servier. AT reports participation in the ORION-4 trial DSMB. HW reports grant support paid to his institution for the HEART-FID Study from American Regent, Dal GenE Study from DalCor Pharma UK, AEGIS-II study from CSL Behring, ISCHEMIA and MINT studies from the US National Institutes of Health, CLEAR Outcomes Study from Esperion Therapeutics, SOLIST-WHF and SCORED trials from Sanofi Aventis Australia, and Librexia AF and ACS studies from Janssen; consulting fees for serving on steering committees for the GenE Study from DalCor Pharma UK, the AEGIS-II study from CSL Behring, the SOLIST-WHF and SCORED Trials from Sanofi Aventis Australia, the CLEAR Outcomes Study from Esperion Therapeutics, and the Librexia AF and ACS studies from Janssen; accommodation support paid to self for attendance at the clinical trial forum 2022 and 2023 from SAHMRI; being chair of the DSMB for the EVIDENCE study; and being on the advisory board of CSL Behring. JA reports previous grants to Oxford University for the Medical Research Council/British Heart Foundation Heart Protection Study, SEARCH, and HPS2-THRIVE trials; being an unpaid data monitoring committee member for the Woman2, So START, and ReSTART trials; and being an unpaid chair of the British Heart Foundation Clinical Studies Committee. AK reports salary support from a NHMRC fellowship; research support from a NHMRC programme grant, Abbott, Amgen, Bayer, Mylan, Novartis, and Sanofi; speaker fees from Novartis; participation on Kowa Safety and Data Monitoring Committee; and receiving drugs for research trials from Viatris and Aspen. JS reports research grants to the University of Sydney from the NHMRC Australia; research contracts to the University of Sydney from Bayer, Roche, Bristol Myers Squibb, Astra Zeneca, Amgen, Pfizer, and MSD; consulting or advisory board fees from FivepHusion paid to the University of Sydney; and being an unpaid STAREE DSMB chair. RCo reports being supported by grants to the University of Oxford from the British Heart Foundation, UK Medical Research Council. Merck, Novartis, Cancer Research UK, AstraZeneca, Wellcome Trust, and Regeneron Pharmaceuticals; having a patent for a statin-related myopathy genetic test licensed to University of Oxford from Boston Heart Diagnostics (RCo has waived any personal reward with any share in royalty and other payments waived in favour of the Nuffield Department of Population Health, University of Oxford) and being chair of the PROMINENT trial data monitoring committee, deputy chair of not-for-profit clinical trial company PROTAS, and chief executive of UK Biobank. CB reports receiving funding to his research institution from Boehringer Ingelheim and Eli Lilly for the EMPA-KIDNEY trial; funding from the UK Medical Research Council (Population Health Research Unit Director, Capital award, Therapy Acceleration Laboratory Award); funding for the University of Oxford from the UK NIHR HTA Programme (17/140/02); being coapplicant for a substantive site award received from Health Data Research UK; unpaid DSMB membership for chairing trials run by Merck, the NIHR HTA, and the British Heart

Foundation; and being the unpaid chair for work conducted by the European Society of Cardiology and NIHR HTA. All other authors declare no competing interests.

Data sharing

Individual participant data from each contributing trial have been provided to the Cholesterol Treatment Trialists' Collaboration on the understanding that they would be used only for the purpose of the Cholesterol Treatment Trialists' meta-analyses and would not be released to others. Requests for such data should be made directly to the data custodians of each trial. The Cholesterol Treatment Trialists' data policy can be found at https://www.cttcollaboration.org/.

Acknowledgments

The work of the CTT Collaboration was funded by the British Heart Foundation (PG/18/16/33570 and CH/1996001/9454), UK Medical Research Council (MC_UU_00017/4), and Australian National Health and Medical Research Council (GNT1037786 and GNT1150467). Although individual trials that were contributing data to the analyses were funded by the pharmaceutical industry, as well as by charities and government organisations, the Cholesterol Treatment Trialists' Collaboration has not received grant funding from industry. Further details are available at: www.cttcollaboration.org. We thank all the participants who originally took part in the included trials, without whom this research would not be possible. We also thank Samantha Briggs and Clare Mathews for their valuable administrative assistance in preparing this report.

References

- Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. J Am Coll Cardiol 2020; 76: 2982–3021.
- 2 Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010; **375**: 2215–22.
- 3 Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. *Lancet* 2010; 376: 1670–81.
- Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008; 371: 117–25.
- 6 Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388: 2532–61.
- 6 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010; 375: 735–42.
- Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556–64.
- 8 Cholesterol Treatment Trialists' (CTT) Collaboration. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J 2016; 176: 63–69.
- Clinical Data Interchange Standards Consortium. Clinical Data Interchange Standards Consortium study data tabulation model. https://www.cdisc.org/standards/foundational/sdtm (accessed Dec 19, 2022).
- 10 Cholesterol Treatment Trialists' Collaboration. Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. *Clin Trials* 2022; 19: 593–604.
- 11 Royal Pharmaceutical Society. Martindale: the complete drug reference. https://www.pharmaceuticalpress.com/products/ martindale-the-complete-drug-reference/ (accessed March 19, 2024).
- 12 Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. *Clinical chemistry and laboratory medicine: CCLM/FESCC* 2002; 40: 78–89.
- 13 WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF Consultation. Geneva: World Health Organization, 2016.

- 14 WHO. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. Geneva: World Health Organization, 2011.
- 15 Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer: worldwide evidence 1985–1990. Oxford: Oxford University Press, 1990.
- 16 Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: e285–350.
- 17 Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
- 18 Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–59.
- 19 Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet* 2022; 400: 832–45.
- 20 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22.
- 21 Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. *Lancet* 2003; 361: 2024–31.
- 22 Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2002; **287**: 3215–22.
- 23 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383–89.
- 24 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7–22.
- 25 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Engl J Med* 1995; 333: 1301–07.
- 26 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996; **335**: 1001–09.
- 27 Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339: 1349–57.
- 28 Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360: 1623–30.
- 29 Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149–58.
- 30 Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–61.
- 31 Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 372: 1231–39.
- 32 Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395–407.
- 33 Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2021–31.

- 34 Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). *Diabetes Care* 2006; 29: 1478–85.
- 35 Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005; **353**: 238–48.
- 36 Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004; 364: 685–96.
- 37 de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16.
- 38 Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010; **376**: 1658–69.
- 39 Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504.
- 40 LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35.
- 41 Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med 2023; 389: 687–99.
- 42 Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55: 1209–16.
- 43 Livingstone SJ, Looker HC, Akbar T, et al. Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS). *Diabetologia* 2016; **59**: 299–306.
- 44 UK Biobank. Data-field 30750. https://biobank.ndph.ox.ac.uk/ showcase/field.cgi?id=30750 (accessed Feb 27, 2024).
- 45 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
- 46 Schwartz GG, Leiter LA, Ballantyne CM, et al. Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease. *Diabetes Care* 2020; 43: 1077–84.
- 47 Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* 2015; 385: 351–61.
- 48 Glechner A, Harreiter J, Gartlehner G, et al. Sex-specific differences in diabetes prevention: a systematic review and metaanalysis. *Diabetologia* 2015; 58: 242–54.
- 9 Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet* 2012; 380: 565–71.
- 50 Marschner IC, Colquhoun D, Simes RJ, et al. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. J Am Coll Cardiol 2001; 38: 56–63.
- 51 Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350–57.
- 52 Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol* 2017, 5: 431–37.
- 53 European Federation of Clinical Chemistry and Laboratory Medicine. EFLM biological variation database. https:// biologicalvariation.eu/search?query=Haemoglobin%20A1c%20 (NGSP) (accessed Dec 19, 2022).
- 54 National Glycohemoglobin Standardization Program. College of American Pathologists (CAP) survey data. https://ngsp.org/ CAPdata.asp (accessed Dec 19, 2022).